Subcutaneous Injection
Patients with hereditary angioedema prefer daily oral treatment over periodic injections
BOSTON — Patients with hereditary angioedema preferred daily pills over periodic subcutaneous injections for prophylactic care, according to a poster at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
FDA approves first twice-a-year, subcutaneous injection for multiple sclerosis
Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary progressive multiple sclerosis, according to a company press release.
‘On’ time improvement significant at day 3 with combination therapy for Parkinson’s
Improvements in “on” time were observed as early as day 3 after treatment initiation with an investigational subcutaneous combination therapy for Parkinson’s disease, which also led to significant improvement by day 7, data show.
Ajovy superior to placebo at 12 weeks for episodic migraine in young people
Ajovy offers “significant efficacy” compared with placebo to address episodic migraine in children and adolescents, according to topline results from the phase 3 SPACE study.
European Commission authorizes subcutaneous Ocrevus for multiple sclerosis
The European Commission has authorized a subcutaneous injection of Ocrevus to treat relapsing multiple sclerosis as well as primary progressive MS, according to the manufacturer.
VIDEO: Subcutaneous ocrelizumab offers similar safety, efficacy to IV administration in MS
DENVER — Subcutaneous administration of ocrelizumab showed similar safety and efficacy profiles to IV administration in multiple sclerosis at 24 weeks, according to David Jones, senior medical director at Genentech.
Positive phase 3 results reported for twice yearly subcutaneous MS therapeutic
Genentech announced positive results from its phase 3 OCARINA II clinical trial evaluating Ocrevus as a twice-a-year, 10-minute subcutaneous injection for those with relapsing forms of MS or primary progressive MS.
Subcutaneous immunotherapy may have slight protective effect against COVID-19
Subcutaneous immunotherapy for house dust mite allergy may slightly protect patients against SARS-CoV-2 infection, especially after the dose-escalation phase, according to a letter published in Clinical and Translational Allergy.
FDA approves injectable for subcutaneous use in adults with generalized myasthenia gravis
Halozyme Therapeutics announced that argenx received FDA approval for Vyvgart Hytrulo with Enhanze for subcutaneous use in adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.
Teriparatide delivered by robotic pill provides higher bioavailability than injection
CHICAGO — An oral robotic pill may provide an alternative delivery method to subcutaneous injection for teriparatide and other biologics, according to a speaker at ENDO 2023.